Roche announced it will acquire Good Therapeutics, a Seattle-based preclinical biotech, for $250 million. The deal makes Roche responsible for developing and commercializing Good's lead program, which seeks to make oncology drugs that target PD-1 proteins more effective, such as Keytruda or Opdivo.
The company said the Phase III CASPIAN study of Imfinzi in first-line, extensive-stage small-cell lung cancer was successful, but did not disclose further details. Roche's Tecentriq is already approved for that indication, which accounts for two-thirds of SCLC cases.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company joins a small but growing list of firms developing drugs targeting CD47, the "don't eat me" immune checkpoint. Another company, further ahead in development, is Forty Seven.
The drug received accelerated approval for combination with Celgene's Abraxane based on Phase III data. According to a study, PD-L1-positive patients account for 26 percent of TNBC patients overall.
The company said it had shared data from the Phase III study with the FDA. However, per FDA regulations, there is a risk that the accelerated approval for hepatocellular carcinoma could be withdrawn.
Experts weighed in on how the move could change the way drugmakers raise money for development programs. But as digital securities as a financial instrument gain traction, they could carry potential risks too.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Two drugs - Pfizer and Merck KGaA's Bavencio and AstraZeneca's Imfinzi - saw Phase III trials fail, while anticipated negative results prompted Roche to withdraw Tecentriq from regulatory review.
Kyoto University's Tasuku Honjo and MD Anderson's James Allison will share the prize for work that led to immunotherapy drugs like Keytruda and Yervoy.
The company aims to get its lead program, developed using its in-house "CRISPRnomics" platform, into the clinic in the next 18 months.
Janssen halts lung cancer and myeloma trials, citing lack of clinical benefit and greater number of patient deaths in combo arm.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Companies to create tests for tissue-agnostic MSI-H and dMMR cancers using Foundation's next-generation sequencing platform.